

Galmed Pharmaceuticals to present at the Israeli Family Practitioners Conference 2015 in Tel Aviv, Israel

About Galmed Pharmaceuticals Ltd.

Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-Hepatitis, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

<https://galmedpharma.investorroom.com/2015-01-14-Galmed-Pharmaceuticals-to-present-at-the-Israeli-Family-Practitioners-Conference-2015-in-Tel-Aviv-Israel>